Selected article for: "antiviral drug and economic impact"

Author: Ali, Mukarram Jamat; Hanif, Muhammad; Haider, Muhammad Adnan; Ahmed, Muhammad Umer; Sundas, FNU; Hirani, Arham; Khan, Izhan Ali; Anis, Khurram; Karim, Amin H.
Title: Treatment Options for COVID-19: A Review
  • Cord-id: 5wicgqhw
  • Document date: 2020_7_31
  • ID: 5wicgqhw
    Snippet: Background: The recent COVID-19 pandemic sweeping the globe has caused great concern worldwide. Due to the limited evidence available on the dynamics of the virus and effective treatment options available, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a huge impact in terms of morbidity and mortality. The economic impact is still to be assessed. Aims: The purpose of this article is to review the evidence for the multiple treatment options available, to consider the future
    Document: Background: The recent COVID-19 pandemic sweeping the globe has caused great concern worldwide. Due to the limited evidence available on the dynamics of the virus and effective treatment options available, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a huge impact in terms of morbidity and mortality. The economic impact is still to be assessed. Aims: The purpose of this article is to review the evidence for the multiple treatment options available, to consider the future of this global pandemic, and to identify some potential options that could revolutionize the treatment of COVID-19. Moreover, this article underscores the sheer importance of repurposing some of the available antiviral and antimicrobial agents that have long been in use so as to have an effective and expeditious response to this widespread pandemic and the need to conduct a multicenter global randomized controlled trial to find an effective single antiviral agent or a cocktail of available antimicrobial agents. Method: We thoroughly searched and reviewed various case reports, retrospective analyses, and in vitro studies published in PubMed, EMBASE, and Google Scholar regarding the treatment options used for SARS-CoV, MERS-CoV, and SARS-CoV-2 since its outbreak in an attempt to highlight treatments with the most promising results. Conclusion: We are currently facing one of the worst pandemics in history. Although SARS-CoV-2 is associated with a lower mortality rate than are SARS-CoV and MERS-CoV, its higher infectivity is making it a far more serious threat. Unfortunately, no vaccine against SARS-CoV-2 or effective drug regimen for COVID-19 currently exists. Drug repurposing of available antiviral agents may provide a respite; moreover, a cocktail of antiviral agents may be helpful in treating this disease. Here, we have highlighted a few available antimicrobial agents that could be very effective in treating COVID-19; indeed, a number of trials are underway to detect and confirm the efficacy of these agents.

    Search related documents:
    Co phrase search for related documents
    • abnormal finding and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7
    • abnormal finding and lopinavir ritonavir: 1
    • action mechanism and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • action mechanism and acute pneumonia: 1, 2, 3, 4, 5, 6
    • action mechanism and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • action mechanism and adenosine analog: 1, 2
    • action mechanism and lopinavir ribavirin: 1
    • action mechanism and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute ards respiratory distress syndrome and lopinavir combination: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and lopinavir hiv inhibitor: 1, 2
    • acute ards respiratory distress syndrome and lopinavir ribavirin: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute pneumonia and lopinavir combination: 1
    • acute pneumonia and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and loperamide chlorpromazine: 1
    • acute respiratory syndrome and loperamide chlorpromazine chloroquine: 1
    • acute respiratory syndrome and lopinavir combination: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lopinavir hiv inhibitor: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory syndrome and lopinavir ribavirin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25